Posted by Michael Wonder on 15 Apr 2020
Fujifilm accelerates production of its influenza anti-viral drug Avigan for COVID-19
15 April 2020 - Fujifilm has announced that it has expanded its manufacturing capacity to significantly increase production of its influenza antiviral drug Avigan (favipiravir) for treating patients with COVID-19.
Fujifilm expects to progressively increase the monthly production of Avigan up to 100,000 treatment courses by July 2020, approximately 2.5 times more compared to the beginning of March, when the company first began its current production run. In addition, Fujifilm plans to further accelerate production up to 300,000 treatment courses* by September 2020.
The Japanese government plans to stockpile two million treatment courses of Avigan, as part of the Japanese government's emergency economic package announced on April 7.
